Metformin increases mammographic breast density: a randomized controlled trial
Background Mammographic breast density (MBD) is directly related to the risk of breast cancer. In vivo and in vitro studies have shown that metformin can reduce the proliferation and growth of breast cancer tissue. The aim of this study was to determine the effect of metformin on MBD in non-diabeti...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2025-01-01
|
| Series: | Basic & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://bccr.tums.ac.ir/index.php/bccrj/article/view/538 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823863892980269056 |
|---|---|
| author | Sadaf Alipour Ladan Hosseini Zohreh Forootan Hadith Rastad Leila Bayani Mahboubeh Abedi Bita Eslami |
| author_facet | Sadaf Alipour Ladan Hosseini Zohreh Forootan Hadith Rastad Leila Bayani Mahboubeh Abedi Bita Eslami |
| author_sort | Sadaf Alipour |
| collection | DOAJ |
| description |
Background Mammographic breast density (MBD) is directly related to the risk of breast cancer. In vivo and in vitro studies have shown that metformin can reduce the proliferation and growth of breast cancer tissue. The aim of this study was to determine the effect of metformin on MBD in non-diabetic premenopausal women. Methods A double-blind, placebo-controlled study was performed. A total of 151 premenopausal women received 500 mg metformin tablets twice a day for 6 months, or a placebo, were included. The changes in MBD were compared between the two groups. Results Final data were evaluated based on 67 and 84 women in the metformin and placebo groups, respectively. Based on results from Ordinal Logistic Regression, the odds of achieving a higher density for the intervention group was approximately 2.33 (95% CI, 1.04 to 5.18) times that of the placebo group. Conclusions This clinical trial showed that consumption of metformin 500 mg twice daily for 6 months is associated with a higher mammographic breast density as compared to the placebo group. As metformin is used very commonly, we suggest that this medicine should be considered as a probable confounding factor when conducting studies about MBD.
|
| format | Article |
| id | doaj-art-1370fde60a34404986d9bbdd7e659584 |
| institution | Kabale University |
| issn | 2228-6527 2228-5466 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | Basic & Clinical Cancer Research |
| spelling | doaj-art-1370fde60a34404986d9bbdd7e6595842025-02-09T08:54:18ZengTehran University of Medical SciencesBasic & Clinical Cancer Research2228-65272228-54662025-01-01154Metformin increases mammographic breast density: a randomized controlled trialSadaf AlipourLadan Hosseini0Zohreh Forootan1Hadith Rastad2Leila Bayani3Mahboubeh Abedi4Bita Eslami5Tehran University of Medical SciencesTehran University of Medical SciencesAlborz University of Medical SciencesTehran University of Medical SciencesBallarat Base HospitalTehran University of Medical Sciences Background Mammographic breast density (MBD) is directly related to the risk of breast cancer. In vivo and in vitro studies have shown that metformin can reduce the proliferation and growth of breast cancer tissue. The aim of this study was to determine the effect of metformin on MBD in non-diabetic premenopausal women. Methods A double-blind, placebo-controlled study was performed. A total of 151 premenopausal women received 500 mg metformin tablets twice a day for 6 months, or a placebo, were included. The changes in MBD were compared between the two groups. Results Final data were evaluated based on 67 and 84 women in the metformin and placebo groups, respectively. Based on results from Ordinal Logistic Regression, the odds of achieving a higher density for the intervention group was approximately 2.33 (95% CI, 1.04 to 5.18) times that of the placebo group. Conclusions This clinical trial showed that consumption of metformin 500 mg twice daily for 6 months is associated with a higher mammographic breast density as compared to the placebo group. As metformin is used very commonly, we suggest that this medicine should be considered as a probable confounding factor when conducting studies about MBD. https://bccr.tums.ac.ir/index.php/bccrj/article/view/538metforminbreast densitymammographyconfounding factorweight |
| spellingShingle | Sadaf Alipour Ladan Hosseini Zohreh Forootan Hadith Rastad Leila Bayani Mahboubeh Abedi Bita Eslami Metformin increases mammographic breast density: a randomized controlled trial Basic & Clinical Cancer Research metformin breast density mammography confounding factor weight |
| title | Metformin increases mammographic breast density: a randomized controlled trial |
| title_full | Metformin increases mammographic breast density: a randomized controlled trial |
| title_fullStr | Metformin increases mammographic breast density: a randomized controlled trial |
| title_full_unstemmed | Metformin increases mammographic breast density: a randomized controlled trial |
| title_short | Metformin increases mammographic breast density: a randomized controlled trial |
| title_sort | metformin increases mammographic breast density a randomized controlled trial |
| topic | metformin breast density mammography confounding factor weight |
| url | https://bccr.tums.ac.ir/index.php/bccrj/article/view/538 |
| work_keys_str_mv | AT sadafalipour metforminincreasesmammographicbreastdensityarandomizedcontrolledtrial AT ladanhosseini metforminincreasesmammographicbreastdensityarandomizedcontrolledtrial AT zohrehforootan metforminincreasesmammographicbreastdensityarandomizedcontrolledtrial AT hadithrastad metforminincreasesmammographicbreastdensityarandomizedcontrolledtrial AT leilabayani metforminincreasesmammographicbreastdensityarandomizedcontrolledtrial AT mahboubehabedi metforminincreasesmammographicbreastdensityarandomizedcontrolledtrial AT bitaeslami metforminincreasesmammographicbreastdensityarandomizedcontrolledtrial |